Summary of Key Points from the Conference Call Industry Overview - The report discusses the performance of the MXCN and CSI300 indices, which lost 1.6% and 0.3% respectively during the week. [1] - Economic data for November broadly missed expectations, particularly in retail sales, which grew by only 1.3% year-over-year. [1] - Fixed Asset Investment (FAI) showed a significant contraction of 10.7% year-over-year. [1] Core Insights and Arguments - President Xi emphasized the importance of expanding domestic demand as a strategic move for economic growth. [1] - The Hainan Free Trade Port has launched island-wide customs clearance operations, increasing the number of duty-free items to over 6000. [1] - The National Development and Reform Commission (NDRC) noted a slowing investment trend since 2025 and called for targeted measures to boost effective investment. [1] - The State Administration for Market Regulation (SAMR) highlighted the need for a unified national market to enhance fair competition and improve antitrust compliance among platform companies. [1] Economic Indicators - The report indicates a double-digit year-over-year contraction in FAI, which is concerning for future economic growth. [1] - Retail sales growth of 1.3% year-over-year is significantly below market expectations, indicating weak consumer demand. [1] Additional Important Information - The report mentions that the China Kickstart publication will resume in the new year, wishing readers a happy holiday season. [1] - The report also includes insights into the performance of various sectors, with materials and financials showing positive performance, while real estate and IT sectors lagged. [9] - The forward price-to-earnings ratios for MXCN and CSI300 are noted to be 12.5x and 14.1x respectively, with expected EPS growth of 4% and 13% for 2025 and 2026. [10] - The report suggests that widespread AI adoption could boost corporate earnings in China by 3% annually over the next decade. [20] Conclusion - The overall economic outlook appears cautious, with significant challenges in consumer spending and investment. The emphasis on domestic demand and regulatory improvements indicates a strategic pivot towards stabilizing and stimulating the economy.

Summary of Key Points from the Conference Call Industry Overview - **Industry**: China Pharma & Biotech - **Trend**: High-value out-licensing from China to multinational corporations (MNCs) is on the rise, with significant growth in transaction values and deal numbers from 2020 to August 2025 [2][6][8]. Core Insights - **Out-licensing Growth**: - The share of out-licensed molecules from China increased from 4% to 19% of global deals, while total transaction consideration rose from 1% to 52% [2][6]. - Over 40% of deals with total transaction consideration exceeding $1 billion originated from China, and more than 20% of MNC collaborations are now from China [2][8]. - **Investment Trends**: - MNCs are increasingly investing in China's biotech assets due to their innovative potential, cost-effectiveness, and strong clinical data [1][23]. - The trend of fund inflow and increased ownership by larger institutions in China Healthcare is becoming prominent [1]. - **Key Companies**: - Top picks in the Pharma/Biotech sector include Hengrui, Hansoh, Ascletis, Abbisko, Fosun Pharm, Sino Biopharm, and Luye [1]. Potential Business Development (BD) Opportunities - **Areas of Interest**: - High interest in next-generation immuno-oncology (IO), oral GLP-1, antibody-drug conjugates (ADC), bispecific antibodies for autoimmune diseases, and siRNA platforms [3][34]. - Candidates with higher safety and efficacy potential in obesity treatments are being prioritized, particularly oral GLP-1 candidates [3][39]. - **Valuation and Differentiation**: - Valuation is crucial for next-generation IO candidates, while differentiation is key for obesity candidates due to market competition [3][39]. Geopolitical Considerations - **Geopolitical Risks**: - Although there are concerns regarding potential restrictions on partnerships with China-developed assets, the likelihood of such restrictions being implemented is considered low [4][21][22]. - The urgency for global drugmakers to replenish their pipelines amid patent cliffs and pricing pressures makes China-originating assets increasingly important [4][22]. Market Dynamics - **US In-licensing**: - China-originated assets accounted for approximately 24% of total US in-licensing deals in 2025, a significant increase from 5% in 2021 [24]. - **Pipeline Replenishment**: - A substantial number of best-selling drugs are set to lose market exclusivity between 2025 and 2030, creating a strong need for global drugmakers to enrich their pipelines [26]. Key Candidates and Products - **Innovative Pipeline**: - Companies like MSD, BMS, and Pfizer are actively seeking next-generation IO candidates and other innovative assets to strengthen their portfolios [29][38]. - **Obesity Treatments**: - Candidates such as oral GLP-1s and muscle-preserving drugs are highlighted for their potential in the obesity market, which is projected to be worth around $30 billion [39][40]. Conclusion - The China Pharma & Biotech sector is experiencing a transformative phase with increasing out-licensing activities and MNC investments. The focus on innovative assets, particularly in oncology and metabolic diseases, presents significant opportunities for growth and collaboration in the coming years.

Summary of Key Points from the Conference Call Industry Overview - The Chinese pharmaceutical sector has shown strong performance, with HSHKBIO up 95% YTD, outperforming major indices [2][4] - Domestic pharma firms have collected 47% of all upfront payments globally for cancer drugs YTD, indicating a robust out-licensing trend [2] Company-Specific Insights 3SBio, SBP, and Hansoh - 3SBio is reiterated as a top pick due to its innovative drug exposure and near-term business development (BD) revenue [2] - SBP and Hansoh are also viewed positively for their high exposure to innovative drugs and potential revenue growth from BD activities [2] CSPC and Kelun - Potential downside surprises are anticipated in Q225 results for CSPC and Kelun due to the lingering impact of Value-Based Pricing (VBP) price cuts on legacy products [2] Financial Estimates and Model Changes SBP - Revenue and margin estimates for SBP have been raised, with EPS estimates for 2025/26/27 increased by 37%/13%/21% due to higher revenue and margin assumptions [3][23] - The acquisition of LaNova Medicines is expected to enhance SBP's innovative drug pipeline and revenue potential [14][18] Hansoh - Hansoh's sales estimates have been adjusted upwards, particularly for combo therapies, with expected peak sales of Rmb8.5 billion in 2029 [3] - EPS estimates for Hansoh for 2025/26/27 have been raised by 3%/5%/5% based on higher revenue expectations [3] Sino Biopharm (SBP) - SBP's total revenue is forecasted to grow at an 8.9% CAGR from 2024-34, driven by stable generics and innovative drugs [8] - The operating profit margin (OPM) is expected to increase from 21.8% in 2024 to 33.4% in 2034 [8] Valuation Adjustments - Price targets for SBP and Hansoh have been raised to HK$11.70 and HK$44.00 respectively, with both stocks rated as "Buy" [5][28] - The pharma sector trades at a median 23.7x 2026E PE and 1.7x 2026E PEG [5] Catalysts and Future Outlook - Key catalysts for the pharma sector include upcoming license-out deals and data readouts from ESMO [4][25] - SBP is expected to announce two more license-out deals in H225, while Hansoh is anticipated to have significant data readouts [4] Risk Factors - The implementation of the 10th round GPO has negatively impacted pharma sales, with a 3.2% decline in QTD Q225 [4] - The potential impact of the 11th round GPO is expected to be limited, but the sector remains sensitive to pricing pressures [4] Additional Insights - The acquisition of LaNova Medicines is seen as a strategic move to enhance SBP's oncology portfolio, with expected milestone revenues contributing significantly [14][18] - The TQC3721 (PDE3/4 inhibitor) is undergoing Phase II trials and is expected to enter Phase III in 2025, indicating promising market potential [15] This summary encapsulates the key insights and financial projections discussed in the conference call, highlighting the performance and outlook of the Chinese pharmaceutical sector and specific companies within it.